DiACardio, a Beer Sheva, Israel-based software company that automates the process of evaluating the Ultrasound of the Heart, raised $1.95m in a post seed financing round.
The round was led by Shengjing Group with participation from new investors CE Ventures and AltaIR, as well as existing investors Agate-Mac Fund and Capital Point Ltd.
The company intends to use the funds to expand its automated toolbox to other areas of the heart that need automation and expand their business in the US, Europe and the emerging markets.
Started in 2010 by 5 Arnon Toussia-Cohen, Chairman, Hila Goldman-Aslan, CEO, Michal Yaacobi, Inventor & Director of R&D, Dr. Noah Liel-Cohen M.D., Inventor, and Prof. Hugo Guterman, Inventor, DiACardio leverages new image processing method and innovative algorithms to provide FDA and CE approved software that evaluates the function of the heart automatically.
The company, which is based in Beer Sheva’s Hi-Tech park and has 10 employees, has already obtained initial sales.